2021
Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans
Angarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li C, Esterlis I, Skosnik PD, Radhakrishnan R, Pittman B, Gueorguieva R, Potenza MN, Finnema SJ, Huang Y, Carson RE, Malison RT. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans. Addiction Biology 2021, 27: e13123. PMID: 34852401, PMCID: PMC8891080, DOI: 10.1111/adb.13123.Peer-Reviewed Original ResearchConceptsCocaine use disorderAnterior cingulate cortexRecent cocaine useSynaptic densityMedial orbitofrontal cortexPrefrontal cortexCocaine useOrbitofrontal cortexUse disordersVentromedial prefrontal cortexPositron emission tomography scanPositron emission tomography studyEmission tomography scanSynaptic vesicle glycoprotein 2AHealthy control subjectsVolume of distributionEmission tomography studiesAcute cocaineControl subjectsTomography scanCocaine exposurePreclinical studiesHC subjectsDendritic spinesLifetime cocaine use
2018
Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects
D’Souza D, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, Ahn K, Bielen K, Carbuto M, Deaso E, D’Souza D, Ranganathan M, Naganawa M, Ranganathan M, D’Souza D, Nabulsi N, Zheng M, Lin S, Huang Y, Carson R, Driesen N, Ahn K, Morgan P, Suckow R, He G, McCarthy G, Krystal J, Johannesen J, Kenney J, Gelernter J, Gueorguieva R, Pittman B. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry 2018, 84: 413-421. PMID: 29499855, PMCID: PMC6068006, DOI: 10.1016/j.biopsych.2017.12.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAzabicyclo CompoundsBrainCognitive DysfunctionDose-Response Relationship, DrugDouble-Blind MethodFemaleGlycine Plasma Membrane Transport ProteinsHumansImidazolesKetamineLong-Term PotentiationMagnetic Resonance ImagingMaleMemory, Short-TermMiddle AgedPositron-Emission TomographySchizophreniaYoung AdultConceptsHealthy control subjectsLong-term potentiationSchizophrenia patientsControl subjectsCognitive impairmentClinical trialsGlyT1 occupancyN-methyl-D-aspartate receptor functionGlycine transporter-1 inhibitorKetamine-induced disruptionKetamine-induced effectsFunctional magnetic resonance imagingMagnetic resonance imagingPositron emission tomographyMemory-related activationF-MKSubstudy 1Schizophrenia subjectsResonance imagingReceptor functionCortical regionsEmission tomographyTarget engagementPotentiationSchizophrenia
2017
A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia
Gunduz‐Bruce H, Kenney J, Changlani S, Peixoto A, Gueorguieva R, Leone C, Stachenfeld N. A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2017, 102: 587-597. PMID: 28294453, DOI: 10.1113/ep086212.Peer-Reviewed Original ResearchConceptsSubgroup of patientsHealthy control subjectsNMDA receptorsControl subjectsDepressed patientsAVP releaseAnimal studiesSchizophrenic subjectsTranslational approachVivo evidenceRecent clinical trialsNMDA receptor functionPlasma arginine vasopressin concentrationNMDA receptor activityHypertonic saline infusionNMDA antagonist ketamineArginine vasopressin concentrationHypertonic salineInverse associationClinical trialsHealthy controlsSaline infusionGlutamate signalingSchizophrenic patientsVasopressin concentration
2012
Impaired Visual Cortical Plasticity in Schizophrenia
Çavuş I, Reinhart RM, Roach BJ, Gueorguieva R, Teyler TJ, Clapp WC, Ford JM, Krystal JH, Mathalon DH. Impaired Visual Cortical Plasticity in Schizophrenia. Biological Psychiatry 2012, 71: 512-520. PMID: 22364738, PMCID: PMC3292767, DOI: 10.1016/j.biopsych.2012.01.013.Peer-Reviewed Original ResearchConceptsHigh-frequency stimulationVisual cortical plasticityCortical plasticityVisual steady-state responseN-methyl-D-aspartate receptor functionHealthy control subjectsLong-term potentiation paradigmLong-term potentiationForm of neuroplasticityRepetitive visual stimulationSustained potentiationControl subjectsVEP assessmentSchizophrenia patientsStandard visual stimuliInfrequent target stimuliCore pathophysiologyReceptor functionPotentiationSchizophreniaVisual stimulationComponent scoresStimulationVisual stimuliBaseline
2011
Using Computational Patients to Evaluate Illness Mechanisms in Schizophrenia
Hoffman RE, Grasemann U, Gueorguieva R, Quinlan D, Lane D, Miikkulainen R. Using Computational Patients to Evaluate Illness Mechanisms in Schizophrenia. Biological Psychiatry 2011, 69: 997-1005. PMID: 21397213, PMCID: PMC3105006, DOI: 10.1016/j.biopsych.2010.12.036.Peer-Reviewed Original ResearchConceptsPrediction-error signallingStory recall taskIllness mechanismsEpisodic memoryRecall taskAssociated emotionsNarrative memoryNarrative languageDopamine neuromodulationDisparate symptomsNarrative understandingHealthy control subjectsDisorganized speechMemorySchizoaffective disorderComputational modelNeural network modelParental educationSchizophreniaCrime storiesPrediction errorDelusionsControl subjectsEmotionsNetwork model
2004
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression. JAMA Psychiatry 2004, 61: 705-713. PMID: 15237082, DOI: 10.1001/archpsyc.61.7.705.Peer-Reviewed Original ResearchConceptsMajor depressive disorderGamma-aminobutyric acidOccipital cortex GABA concentrationsProton magnetic resonance spectroscopyDepressed subjectsGABA concentrationHealthy controlsSubtypes of MDDCortical gamma-aminobutyric acidHealthy control subjectsMetabolite levelsCholine-containing compoundsHealthy comparison subjectsClinical research programSubtype-specific alterationsΓ-aminobutyric acidClinical correlatesMDD patientsControl subjectsDepressive disorderNeurotransmitter levelsGlutamate levelsMajor depressionMDD subtypesOccipital cortex